Skip to main content
Syncona Limited logo

Syncona Limited — Investor Relations & Filings

Ticker · SYNC ISIN · GG00B8P59C08 LEI · 213800X8MBI5VQITLW60 IL Financial and insurance activities
Open in API
Filings indexed 1,030 across all filing types
Latest filing 2023-12-11 Regulatory Filings
Country GG Guernsey
Listing IL SYNC

About Syncona Limited

https://www.synconaltd.com/

Syncona Limited is a life science investment company focused on founding, building, and funding a portfolio of healthcare businesses. The company's strategy is to identify and advance exceptional science to create globally leading companies capable of delivering transformational treatments to patients, particularly in areas with high unmet medical needs. Its portfolio is concentrated in innovative therapeutic areas, including gene therapy, cell therapy, and biologics. Syncona actively manages its companies to reach key value inflection points, aiming to generate significant long-term capital appreciation for shareholders through strategic events such as mergers, acquisitions, and other liquidity events.

Recent filings

Filing Released Lang Actions
Autolus presents clinical data updates
Regulatory Filings Classification · 98% confidence The document is an RNS announcement (RNS Number: 3130W) issued by Syncona Limited on December 11, 2023. The content primarily reports on clinical data updates presented by its portfolio company, Autolus Therapeutics Plc, at the 2023 American Society of Hematology (ASH) Annual Meeting. The document summarizes key findings from clinical studies (FELIX, MCARTY, ALLCAR19) related to their drug candidates (obe-cel, AUTO8). It includes links to the actual presentations/posters and states that the full text of the announcement from Autolus is contained below. Since this is an announcement by Syncona regarding news from a portfolio company, and it contains the full text of the underlying news release (which details clinical data presentations), it functions as a general regulatory announcement. It is not a formal financial report (like 10-K or IR), nor is it solely a management change (MANG) or dividend notice (DIV). Given the nature of reporting on clinical trial data updates and referencing external presentations, the most appropriate classification is Regulatory Filings (RNS), as it is a broad regulatory disclosure that doesn't fit the more specific categories like ER, MDA, or CT.
2023-12-11 English
Transaction in Own Shares
Transaction in Own Shares Classification · 100% confidence The document explicitly announces a 'Transaction in Own Shares' detailing the purchase of 160,000 ordinary shares as part of a previously announced 'share buyback programme'. This directly corresponds to the definition of a company buying back its own shares. The filing uses the RNS format, but the specific content points directly to the 'Transaction in Own Shares' category (POS).
2023-12-11 English
Transaction in Own Shares
Transaction in Own Shares Classification · 100% confidence The document explicitly states 'Transaction in Own Shares' and details the purchase of 160,000 ordinary shares by the company as part of a previously announced 'share buyback programme'. This directly corresponds to the definition of a company buying back its own shares. The filing code 'POS' (Transaction in Own Shares) is the most accurate classification. The presence of the RNS Number and the LSE footer confirms it is a regulatory announcement, but the specific content dictates the classification over the general 'RNS' fallback.
2023-12-08 English
Transaction in Own Shares
Transaction in Own Shares Classification · 99% confidence The document explicitly states 'Transaction in Own Shares' and details the purchase of 160,000 Ordinary Shares as part of a 'share buyback programme'. This directly corresponds to the definition of a company buying back or selling its own shares. The filing is identified by the RNS Number format, which is typical for regulatory announcements, but the specific content points directly to the 'Transaction in Own Shares' category, which maps to code POS. The document length is relatively short (3236 chars) and contains all the necessary details, so it is not classified as a general RPA or RNS.
2023-12-07 English
Transaction in Own Shares
Transaction in Own Shares Classification · 100% confidence The document explicitly states its purpose in the title section: "Transaction in Own Shares". It details the purchase of 160,000 ordinary shares by Syncona Limited as part of its share buyback programme on December 5, 2023. This directly corresponds to the definition of 'Transaction in Own Shares' (Code: POS). The presence of the RNS Number and the closing statement confirming the information is provided by RNS (London Stock Exchange's news service) confirms it is a regulatory announcement, but the specific content dictates the classification over the general RNS fallback.
2023-12-06 English
Transaction in Own Shares
Transaction in Own Shares Classification · 100% confidence The document explicitly states the subject is 'Transaction in Own Shares' and details the purchase of Ordinary Shares as part of a 'share buyback programme'. It provides the date, volume, and price of the shares repurchased. This directly corresponds to the definition of 'Transaction in Own Shares' (Code: POS). The presence of the RNS Number and the footer mentioning RNS as the news service confirms it is a regulatory announcement, but the specific content dictates the POS classification over the general RNS fallback.
2023-12-05 English

Browse filings by year

15 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.